The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA

Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.

wallstreetcnDec 9 11:20

Inovio Pharmaceuticals' INO-3107 Shows Promising Clinical Trial Results, Earns 'Buy' Rating From Analyst

TipRanksDec 5 23:28 · Ratings

Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)

TipRanksDec 5 23:21 · Ratings

Express News | Inovio Pharmaceuticals Inc - No Serious Adverse Events Identified in Retrospective Trial

BreakingsDec 3 21:00

Express News | Inovio Pharmaceuticals Inc - New Data to Inform Re-Dosing Strategy for Rrp Treatment

BreakingsDec 3 21:00

Express News | New Retrospective Data Shows Half of Rrp Patients Treated With Ino-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

BreakingsDec 3 21:00